Cellular protection by erythropoietin: New therapeutic implications?

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 3, 2007, Pages 759-762

  Joyeux Faure, Marie ^a,b,c  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c University Grenoble Alpes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPOETIN OMEGA; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CHRONIC KIDNEY FAILURE; ERYTHROPOIESIS; HEART PROTECTION; HEMATOPOIESIS; HUMAN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 36348966705     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.127357     Document Type: Article

References (40)

1. Baker JE (2005) Erythropoietin mimics ischemic preconditioning. Vascul Pharmacol 42:233-241.
2. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, and Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643-651.
3. Bogoyevitch MA (2004) An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63:208-216.
4. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101:14907-14912.
5. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, and Cerami A (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526-10531.
6. Bullard AJ, Govewalla P, and Yellon DM (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100:397-403.
7. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, and Semenza GL (2003) Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108:79-85.
8. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, and Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100:4802-4806.
9. Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, Genc S, Genc K, Sagiroglu E, Cerami A, et al. (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99:2258-2263.
10. Chong ZZ, Kang JQ, and Maiese K (2002a) Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106:2973-2979.
11. Chong ZZ, Kang JQ, and Maiese K (2002b) Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 22:503-514.
12. Digicaylioglu M and Lipton SA (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641-647.
13. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505.
14. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, et al. (2003) Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 100:6741-6746.
15. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, et al. (2005) A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 102:2046-2051.
16. Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, Calapai G, De Vico G, Piedimonte G, Salpietro FM, et al. (2002) Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 99:5627-5631.
17. Hamed S, Barshack I, Luboshits G, Wexler D, Deutsch V, Keren G, and George J (2006) Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 27:1876-1883.
18. Hirata A, Minamino T, Asanuma H, Sanada S, Fujita M, Tsukamoto O, Wakeno M, Myoishi M, Okada K, Koyama H, et al. (2005) Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 19:33-40.
19. Joyeux-Faure M, Godin-Ribuot D, and Ribuot C (2005) Erythropoietin and myocardial protection: what's new? Fundam Clin Pharmacol 19:439-446.
20. Joyeux-Faure M, Ramond A, Beguin PC, Belaidi E, Godin-Ribuot D, and Ribuot C (2006) Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam Clin Pharmacol 20:51-56.
21. Krause KT, Jaquet K, Geidel S, Schneider C, Mandel C, Stoll HP, Hertting K, Harle T, and Kuck KH (2006) Percutaneous endocardial injection of erythropoietin: assessment of cardioprotection by electromechanical mapping. Eur J Heart Fail 8:443-450.
22. Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Khai NC, Maruyama R, Ogino A, et al. (2006a) Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113:535-543.
23. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, and Fujiwara H (2006b) Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 71:684-694.
24. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, and Schoemaker RG (2004) Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44:473-479.
25. Liu X, Xie W, Liu P, Duan M, Jia Z, Li W, and Xu J (2006) Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78:2255-2264.
26. Maiese K, Li F, and Chong ZZ (2004) Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 25:577-583.
27. Maiese K, Li F, and Chong ZZ (2005) New avenues of exploration for erythropoietin. JAMA 293:90-95.
28. Mitsuma W, Ito M, Kodama M, Fuse K, Okamura K, Minagawa S, Kato K, Hanawa H, Toba K, Nakazawa M, et al. (2006) Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 344:987-994.
29. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, and Talan MI (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100:11612-11617.
30. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, and Talan MI (2006) Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316:999-1005.
31. Olsen NV (2003) Central nervous system frontiers for the use of erythropoietin. Clin Infect Dis 37 (Suppl 4):S323-S330.
32. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999-1007.
33. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, and Sasaki R (1998) Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253:26-32.
34. Shi Y, Rafiee P, Su J, Pritchard KA Jr., Tweddell JS, and Baker JE (2004) Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 99:173-182.
35. Shingo T, Sorokan ST, Shimazaki T, and Weiss S (2001) Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21:9733-9743.
36. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, et al. (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37:1775-1780.
37. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98:4044-4049.
38. Smith KJ, Bleyer AJ, Little WC, and Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538-548.
39. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, and Schoemaker RG (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46:125-133.
40. van der Meer P, Voors AA, Lipsic E, van Gilst WH, and van Veldhuisen DJ (2004) Erythropoietin in cardiovascular diseases. Eur Heart J 25:285-291.